Effects of the Topical OLEOZON®, Ketoconazole and Terbinafine on Skin Lesions and Dermatophytes in Patients with Epidermophitosis
DOI:
https://doi.org/10.63623/4s39r825Keywords:
Skin lesions, Dermatophytes, Epidermophytosis, Topical Oleozon®, Ketoconazole, TerbinafineAbstract
Dermatophytoses are fungal infections that are frequently diagnose all over the world. Dermatophytes are keratinophilic filamentous fungi that damage nails, skin, and hair. Treatment for dermatophytosis can be topical (creams, lotions, or ointments, such as ketoconazole and terbinafine) or systemic. Topical OLEOZON® (ozonated sunflower oil) is registered in Cuba for the treatment of Epidermophytosis. The aims of this post-hoc analysis was to evaluate and compare, for the first time, the effects of topical OLEOZON® versus ketoconazole and terbinafine on skin lesions and dermatophyte clearance in cuban patients with Epidermophytosis. The present analysis was obtained from the data of patients included in a previous Phase III comparative study. Efficacy variables include significant reduction in skin lesions and presence of dermatophytes. Statistical analysis was performed using the intention-to-treat approach. Three hundred patients of both sexes with a diagnosis of Epidermophytosis, were randomly assigned to receive topical OLEOZON®, or ketoconazole, or terbinafine. At the six weeks, all treatments significantly reduced all skin lesions and the presence of dermatophytes. However, there were no significant differences between groups in the comparisons made. The treatments were safe and well tolerated. It is concluded that topical OLEOZON® showed comparable effects to ketoconazole and terbinafine in reducing all skin lesions and the presence of dermatophytes in Cuban patients with Epidermophytosis, with a favorable impact on the clinical and mycological cure rate of these patients. These findings support the potential utility of OLEOZON® as an affordable, well-tolerated alternative in settings where conventional antifungal options may be limited or contraindicated.
References
[1]Martinez-Rossi NM, Peres NTA, Bitencourt TA, Martins MP, Rossi A. State-of-the-art dermatophyte infections: Epidemiology aspects, pathophysiology, and resistance mechanisms. Journal of Fungi, 2021, 7(8), 629-633. DOI: 10.3390/jof7080629
[2]Jartarkar SR, Patil A, Goldust Y, Cockerell CJ, Schwartz RA, Grabbe S, et al. Pathogenesis, immunology and management of dermatophytosis. Journal of Fungi, 2021, 8(1), 39-42. DOI: 10.3390/jof8010039
[3]Begum J, Mir NA, Lingaraju MC, Buyamayum B, Dev K. Recent advances in the diagnosis of dermatophytosis. Journal of Basic Microbiology, 2020, 60(4), 293-303. DOI: 10.1002/jobm.201900675
[4]Segal E, Elad D. Human and zoonotic dermatophytoses: Epidemiological aspects. Frontiers in Microbiology, 2021, 12, 713532. DOI: 10.3389/fmcib.2021.713532
[5]Moskaluk AE, VandeWoude S. Current topics in dermatophyte classification and clinical diagnosis. Pathogens, 2022, 11(9), 957-963. DOI: 10.3390/pathogens11090957
[6]Durdu M, Ilkit M, Tamadon Y, Tolooe A, Rafati H, Seyedmousavi S. Topical and systemic antifungals in dermatology practice. Expert Review of Clinical Pharmacology, 2017, 10(2), 225-237. DOI: 10.1080/17512433.2017.1263564
[7]Molerio J, Menéndez S, Díaz W, Lezcano I, León F, Ledea O, et al. Registro sanitario sobre la aplicación del aceite de girasol ozonizado OLEOZON en la Epidermofitosis. No.1498, Ciudad de La Habana, Cuba, 1999.
[8]Lezcano I, Moleiro J, Gómez M, Contreras R. Actividad in vitro del OLEOZON frente a agentes etiológicos de infecciones en la piel. Revista CENIC Ciencias Biológicas, 1998, 29, 209-212.
[9]Sechi LA, Lezcano I, Nunez N, Espim M, Duprè I, Pinna A, et al. Antibacterial activity of ozonized sunflower oil (OLEOZON). Journal Application Microbiology, 2001, 90(2), 279-284. DOI: 10.1046/j.1365-2672.2001.01235.x
[10]Lezcano I, Nuñez N, Espino M, Gómez M. Antibacterial activity of ozonized sunflower oil, OLEOZON, against Staphylococcus aureus and Staphylococcus epidermitis. Ozone Science & Engineering, 2000, 22, 207-214. DOI: 10.1080/01919510008547221
[11]Rodríguez MD, Menéndez S, Gómez M. Estudio teratogénico del aceite ozonizado. Primer Congreso Iberolatinoamericano de Aplicaciones del Ozono. Centro Nacional de Investigaciones Cientificas-Centro de Investigaciones Medico-Quirurgicas (CNIC-CIMEQ), 1990, 31.
[12]Acevedo A, González F, Molerio J, González B, León A, Hernández J. Ensayo de toxicidad subcrónica dérmica de 120 días del aceite ozonizado, OLEOZON, en ratas Cenp. Avances en Biotecnología Moderna, 1997, 4, 1-4.
[13]Sánchez GM, León SF, Rodriguez TC, Merino NC, Sam SR, Cedeño MP, et al. Estudio de la toxicidad aguda dérmica del aceite ozonizado OLEOZON en ratas. Revista CENIC Ciencias Biológicas, 1997, 28(1), 35-38.
[14]Remigio AC, González Y, Zamora Z, Fonseca G, Molerio J. Evaluación genotóxica del OLEOZON mediante los ensayos de micronúcleos en médula ósea y sangre periférica de ratón. Revista CENIC Ciencias Biológicas, 1998, 29(3), 200-202.
[15]Arteaga P, Mirabal JM, Bada AM, González B, Zamora Z, Remigio AC. Clasificación toxicológica del OLEOZON. Revista CENIC Ciencias Biológicas, 2001, 32(1), 57-58.
[16]Díaz M, García G, García K, Sánchez Y, Tillan J. Evaluación de la irritabilidad dérmica, oftálmica y el efecto sensibilizante del OLEOZON® Tópico. Revista Electrónica de Veterinaria, 2006, VII(11), 11-14.
[17]Martínez G, Re L, Pérez G, Horwat R. Las aplicaciones médicas de los aceites ozonizados, actualización. Revista Española de Ozonoterpia, 2012, 2, 121-139.
[18]Menéndez S, Falcón L, Simón RD. Efficacy of OLEOZON in the treatment of Epidermophytosis. Mycoses, 2002, 45(8), 329-333. DOI: 10.1046/j.14.39-0507.2002.00780.x
[19]Argote M. Generalización del uso del OLEOZON® tópico en el tratamiento de la epidermofitosis de los pies. Speciality thesis Carlos Juan Finlay¨ Hospital, 2006.
[20]Menéndez S, Fernández M, Amoroto M, Uranga R. Eficaciay seguridad del Oleozon® tópico en el tratamiento de pacientes con impétigo. Revista Panamericana Infectología, 2007, 9(2), 23-29.
[21]Menéndez S, González R, Ledea E, Hernández F, León OS, Díaz, M. Ozono: Aspectos básicos y aplicaciones clínicas. Editorial CENIC, 2008a, 10-320.
[22]Menéndez S, Re L, Falcón L, Argote MB. Safety of topical Oleozon® in the treatment of Tinea Pedis: Phase IV clinical trial. International Journal of Ozone Therapy, 2008b, 7, 25-30.
[23]Menéndez S, Falcón L, Maqueira Y. Therapeutic efficacy of topically Oleozon® in patients suffering from onychomycosis. Mycosis, 2011, 54(5), 272-277. DOI: 10.1111/j.1439-0507.2010.01898.x
[24]Alacan L, Fernández JC, González EA, González Y, Gray OR, Sanler E, et al. Comparative study of the efficacy and safety of the ozonated sunflower oil, ketoconazole and terbinafine in patients with dermatophytosis. Journal of Mycology and Infection, 2024, 29(3), 98-107. DOI: 10.17966/JMI.2024.29.3.98
[25]Requerimientos para la notificación y el reporte de eventos adversos graves e inesperados en los ensayos clínicos. Regulación No. 45-2007. Centro para el Control Estatal de los Medicamentos, Equipos y Dispositivos Médicos (CECMED), MINSAP, 2007.
[26]Rudramurthy SM, Shaw D. Overview and update on the laboratory diagnosis of dermatophytosis. Clinical Dermatology Review, 2017, 1, 3-10. DOI: 10.4103/CDR.CDR_35_17
[27]Williams DH, Davis CE. Reporting of assignment methods in clinical trials. Controlled Clinical Trials, 1994, 15: 294-298. DOI: 10.1016/0197-2456(94)90045-0
[28]Urban K, Chu S, Scheufele C, Giesey RL, Mehrmal S, Uppal P. The global, regional, and national burden of fungal skin diseases in 195 countries and territories: A cross-sectional analysis from the Global Burden of Disease Study 2017. JAAD International, 2021, 2, 22-27. DOI: 10.1016/j.jdin.2020.10.003
[29]Hayette MP, Sacheli R. Dermatophytosis, trends in epidemiology and diagnostic approach. Current Fungal Infection Reports, 2015, 9(3), 164-179. DOI: 10.1007/s12281-015-0231-4
[30]Ilkit M, Durdu M. Tinea pedis: the etiology and global epidemiology of a common fungal infection. Critical Reviews in Microbiology, 2015, 41(3), 374-388. DOI: 10.3109/1040841X.2013.856853
[31]Chollet A, Cattin V, Fratti M, Mignon B, Monod M. Which fungus originally was Trichophyton mentagrophytes? Historical review and illustration by a clinical case. Mycopathologia, 2015, 180, 1-5. DOI: 10.1007/s11046-015-9893-2
[32]Gnat S, Nowakiewicz A, Zięba P. Taxonomy of dermatophytes–the classification systems may change but the identification problems remain the same. Postępy Mikrobiologii-Advancements of Microbiology, 2019, 58(1), 49-58. DOI: 10.21307/PM–2019.58.4.367
[33]Gupta AK, Foley KA, Versteeg SG. New antifungal agents and new formulations against dermatophytes. Mycopathologia, 2017, 182, 127-141. DOI: 10.1007/s11046-016-0045-0
[34]Choi FD, Juhasz MLW, Atanaskova Mesinkovska N. Topical ketoconazole: a systematic review of current dermatological applications and future developments. Journal of Dermatological Treatment, 2019, 30(8), 760-771. DOI: 10.1080/09546634.2019.1573309
[35]Maxfield L, Preuss CV, Bermudez R. Terbinafina. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Julio César Fernández Travieso, Evelyn Anie González Pla, Lazara Alacán Pérez, Yeni González Liriano, Elizabeth Sanler Wong, Maylen Rodríguez Ordaz, José Alejandro Díaz Cardoso, Ada Bermúdez Sori, Ana Labrada Carballo, Yenney Reyes Nuñez, Yanay Fernández Domínguez, Manuel Eduardo Cordero Hernández, Rolando Uranga Piña (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
